Debunking Ken Fisher: Performance, Fees, Net Worth

2. Johnson & Johnson (NYSE:JNJ)

On the other hand, in Johnson & Johnson (NYSE:JNJ), Fisher Investments increased its stake by 3% to 11.50 million shares valued at $1.52 billion during the second quarter. The pharmaceutical giant has recently announced several positive results from its trials. Its Xarelto blood thinner showed a reduction in the risk of major cardiovascular events in combination with aspirin. In other news, the company has been under pressure, alongside its other peers in the pharmaceutical industry, from the government, regarding high drug prices. At the end of August, Michigan state legislators introduced a bill that would require drug makers to justify price hikes, joining several other states that took similar actions to address price hikes. There were 72 funds in our database long Johnson & Johnson (NYSE:JNJ) at the end of the second quarter, up by two compared to the end of March.

Follow Johnson & Johnson (NYSE:JNJ)